ChAdOx1.tHIVconsv1
- Generic Name
- ChAdOx1.tHIVconsv1
RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
Phase 1
Not yet recruiting
- Conditions
- Acute HIV InfectionHIV InfectionsPLWHART
- Interventions
- Biological: VRC07-523LSBiological: PGDM1400LSOther: PlaceboBiological: ChAdOx1.tHIVconsv1Biological: ChAdOx1.HIVconsv62Biological: MVA.tHIVconsv4Biological: A244d11 gp120Biological: ALFQ
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT06484335
- Locations
- 🇹ðŸ‡
The Faculty of Medicine, Chulalongkorn University/ King Chulalongkorn Memorial Hospital, Pathum Wan, Bangkok, Thailand
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
Phase 1
Suspended
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2025-04-25
- Target Recruit Count
- 45
- Registration Number
- NCT06071767
- Locations
- 🇧🇷
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS, Porto Alegre, Rio Grande Do Sul, Brazil
🇺🇸University of California, San Diego AntiViral Research Center CRS, San Diego, California, United States
🇺🇸Ponce de Leon Center CRS, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath